FCMV
LYEL icon

Foresite Capital Management V’s Lyell Immunopharma LYEL Stock Holding History

Foresite Capital Management V’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.57M Hold
477,078
– – 3.53% 6
2025
Q4 		$14.7M Hold
477,078
– – 8.93% 5
2025
Q3 		$7.75M Buy
477,078
+70,426
+17% +$804K 7.12% 5
2025
Q2 		$3.59M Hold
406,652
– – 4.45% 6
2025
Q1 		$4.38M Hold
406,652
– – 4.99% 5
2024
Q4 		$5.21M Buy
+406,652
New +$8.06M 4.33% 6

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Foresite Capital Management V's LYEL Position: Q1 2026 in Review

Foresite Capital Management V held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 477,078 shares worth $9.57M. The position accounts for 3.53% of the portfolio, ranked #6.

Foresite Capital Management V first reported a position in LYEL in Q4 2024 and has held it in 6 quarters since. The position peaked at $14.7M in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Foresite Capital Management V held 477,078 shares of Lyell Immunopharma worth $9.57M as of Q1 2026.
  • Foresite Capital Management V left its Lyell Immunopharma share count unchanged in Q1 2026.
  • Lyell Immunopharma made up 3.53% of Foresite Capital Management V's portfolio in Q1 2026, its #6 holding.
  • Foresite Capital Management V first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 6 quarters since.
  • Foresite Capital Management V's Lyell Immunopharma position peaked at $14.7M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Foresite Capital Management V's 13F filing for Q1 2026, filed 15 May 2026.